Novel Rx
3 weeks ago
#EULAR2024 OP0295 Approriate patient stratification matters in trials. H2H RCT of Tocilizumab vs Rituximab in refractory #SSc-ILD (failed CyC), stratified based on RNA-seq of lungs biopsy showed improved efficacy in TCZ with low B-cell lineage expression signature @RheumNow https://t.co/7ME3Bd2PeM
3 weeks ago
#EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ikaros) was well tolerated with
efficacy signal (SLEDAI-2K & CLASI-50). Effect and safety profile were numerically better in the lowest dose @RheumNow https://t.co/Bjk9zBRmVo
3 weeks ago
Does TCZ switch off GCA histopathologically?
GCA pts still on TCZ (median 2.4y duration) had repeat temporal artery biopsy (contralat)
Despite serological remission on TCZ, a heap had active histopath findings & PET still active. Scary
#EULAR2024 OP0233 Reggio Emilia @RheumNow https://t.co/TKBUP5p4R0
3 weeks ago
Greatest chance of sustained drug-free remission (DFR) is seen in early RA pts, NEVER requiring a biologic (esp if seronegative blue line). ERA on biologics never achieve DFR (yellow). Leiden EAC clinic study of 627 ERA pts Abstr# POS0615 #EULAR2024 https://t.co/zpCG6oSE3T
Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the…
3 weeks ago
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024
3 weeks ago
Day 1 #EULAR2024 Do you want to learn about the effectiveness of rituximab for systemic features of #Sjogren and potential strategies to overcome non-response? Please come to my talk today (OP0076) and say hi 👋🏼 😃 Room C7 at 1720 hr CET @RheumNow https://t.co/uo2ivC5AeY
Poster Hall